For information about COVID-19, including symptoms and prevention, please read our COVID-19 patient guide. If you need to see your provider, please contact us to see if a Video Visit is right for you. Please also consider supporting Weill Cornell Medicine’s efforts against the pandemic.
Myeloma Center

You are here

Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma.

TitleSerum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma.
Publication TypeJournal Article
Year of Publication2015
AuthorsVij R, Wang M, Jagannath S, Niesvizky R, Jakubowiak AJ, Kavalerchik E, Huang M, Siegel DS
JournalLeuk Lymphoma
Volume56
Issue10
Pagination2959-61
Date Published2015
ISSN1029-2403
KeywordsAntineoplastic Agents, Biomarkers, Tumor, Drug Resistance, Neoplasm, Humans, Immunoglobulin Light Chains, Multiple Myeloma, Oligopeptides, Prognosis, Proteasome Inhibitors, Recurrence, Retrospective Studies, Treatment Outcome
DOI10.3109/10428194.2015.1020801
Alternate JournalLeuk. Lymphoma
PubMed ID25699653